Compare CWT & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWT | CLDX |
|---|---|---|
| Founded | 1926 | N/A |
| Country | United States | United States |
| Employees | 1105 | N/A |
| Industry | Water Supply | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1997 | 1995 |
| Metric | CWT | CLDX |
|---|---|---|
| Price | $45.35 | $32.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 15 |
| Target Price | $53.75 | ★ $62.50 |
| AVG Volume (30 Days) | 383.7K | ★ 1.6M |
| Earning Date | 10-29-2026 | 11-09-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $963,695,000.00 | $12,743,000.00 |
| Revenue This Year | $9.24 | $19.74 |
| Revenue Next Year | $6.80 | $438.11 |
| P/E Ratio | $45.59 | ★ N/A |
| Revenue Growth | 6.41 | ★ 87.78 |
| 52 Week Low | $41.29 | $22.10 |
| 52 Week High | $53.82 | $45.14 |
| Indicator | CWT | CLDX |
|---|---|---|
| Relative Strength Index (RSI) | 28.46 | 32.85 |
| Support Level | $44.63 | $28.51 |
| Resistance Level | $45.58 | $35.10 |
| Average True Range (ATR) | 0.80 | 2.12 |
| MACD | -0.16 | -0.45 |
| Stochastic Oscillator | 10.88 | 17.88 |
California Water Service Group is a U.S. water and utilities holding company based in California. The company provides water utility and other related services in California, Washington, New Mexico, Hawaii and Texas through its wholly-owned subsidiaries. The bulk of the company's business consists of the production, purchase, storage, treatment, testing, distribution, and sale of water for domestic, industrial, public, and irrigation uses, and the provision of water for domestic and municipal fire protection services.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.